This is a summary of the study setup and most important findings of a scientific paper focusing on health economics of Woulgan published in Journal of Wound Care (JWC) July 2019. It is part of our “In a nutshell” series where we report the basics of all the scientific papers making up the Evidence for … Continue reading ›
This is a summary of the study setup and most important findings of a scientific paper published in Journal of Wound Care (JWC) in September 2018. It is part of our “In a nutshell” series where we report the basics of all the scientific papers making up the Evidence for Woulgan, to make the findings … Continue reading ›
The Woulgan team is proud to present the new Woulgan user guidance video! “A picture speaks more than a thousand words” is a famous saying. With the time restrictions experienced by nurses, we hope that our brand new video will help you to get a quick grasp of how Woulgan reactivates stalled healing, how to … Continue reading ›
At any point in the healing trajectory, a wound can become stalled. That is, the wound initially began to heal, but patient- or wound-related factors have prevented the wound from continuing to heal in an orderly and timely manner. The wound is stuck — ‘stalled’ — in the inflammatory phase, as indicated by a lack … Continue reading ›
The costs of obesity to the health care system are plastered across the headlines — and yet, few recognise that the financial impact of caring for wounds is similar to that of obesity.[1] In fact, an estimated 2–4% of healthcare expenditure across Europe is eaten up by wound care.[2] A lot of this wound care … Continue reading ›
Biotec BetaGlucans’ work on beta-glucan activity has roots in discoveries made at the University of Tromsø, Norway, and Biotec Pharmacon’s early work developing a portfolio of beta-1,3/1,6-glucan products that have been sold worldwide in the animal health and consumer markets. Despite its origins in the Arctic Circle, the company has since closely collaborated with leading … Continue reading ›